TCDA - Tricida, Inc. - SEC Form 4 Insider Trading Screener
100 results - 
- 
- 
- 
- 
- 
- - - - - | TC | cnt | 1d | 1w | 1m | 6m |
X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Insider Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2020-07-15 | TCDA | Klaerner Gerrit | Pres, CEO | S - Sale | $26.33 | -4,000 | 573,316 | -1% | -$105,320 | ||||||
2020-07-01 | TCDA | Klaerner Gerrit | Pres, CEO | S - Sale | $27.15 | -4,000 | 576,644 | -1% | -$108,600 | ||||||
2020-06-15 | TCDA | Klaerner Gerrit | Pres, CEO | S - Sale | $25.97 | -4,000 | 580,644 | -1% | -$103,869 | ||||||
2020-06-01 | TCDA | Klaerner Gerrit | Pres, CEO | S - Sale | $26.23 | -4,000 | 584,644 | -1% | -$104,920 | ||||||
2020-05-15 | TCDA | Klaerner Gerrit | Pres, CEO | S - Sale | $31.55 | -4,000 | 588,644 | -1% | -$126,220 | ||||||
| M | 2020-05-11 | TCDA | Parker Geoffrey M. | Chief Fin. Officer, EVP | P - Purchase | $30.09 | +35,000 | 231,165 | +18% | +$1,053,203 | |||||
| D | 2020-05-08 | TCDA | Otto Dawn Parsell | EVP, Clinical Development | S - Sale+OE | $31.98 | -3,000 | 255 | -92% | -$95,940 | |||||
| D | 2020-05-05 | TCDA | Otto Dawn Parsell | EVP, Clinical Development | S - Sale+OE | $30.14 | -1,250 | 255 | -83% | -$37,680 | |||||
2020-05-01 | TCDA | Klaerner Gerrit | Pres, CEO | S - Sale | $27.98 | -4,000 | 592,644 | -1% | -$111,906 | ||||||
| DM | 2020-04-28 | TCDA | Otto Dawn Parsell | EVP, Clinical Development | S - Sale+OE | $31.39 | -4,250 | 255 | -94% | -$133,415 | |||||
2020-04-15 | TCDA | Klaerner Gerrit | Pres, CEO | S - Sale | $27.47 | -4,000 | 596,644 | -1% | -$109,891 | ||||||
2020-04-06 | TCDA | Klaerner Gerrit | Pres, CEO | S - Sale | $24.22 | -4,000 | 600,644 | -1% | -$96,880 | ||||||
2020-03-16 | TCDA | Klaerner Gerrit | Pres, CEO | S - Sale | $23.91 | -4,000 | 604,644 | -1% | -$95,640 | ||||||
2020-03-10 | TCDA | Parker Geoffrey M. | Chief Fin. Officer, EVP | P - Purchase | $29.46 | +5,000 | 196,165 | +3% | +$147,300 | ||||||
| D | 2020-03-02 | TCDA | Otto Dawn Parsell | EVP, Clinical Development | S - Sale+OE | $31.84 | -4,250 | 255 | -94% | -$135,316 | |||||
| D | 2020-03-02 | TCDA | Hejlek Edward J | EVP, GC, Secy. | S - Sale+OE | $31.66 | -10,000 | 19,153 | -34% | -$316,616 | |||||
2020-03-02 | TCDA | Klaerner Gerrit | Pres, CEO | S - Sale | $31.53 | -4,000 | 608,644 | -1% | -$126,120 | ||||||
2020-02-18 | TCDA | Klaerner Gerrit | Pres, CEO | S - Sale | $36.10 | -4,000 | 612,644 | -1% | -$144,400 | ||||||
| D | 2020-02-05 | TCDA | Stahl Wilhelm | Chief Tech Officer, SVP | S - Sale+OE | $38.91 | -500 | 14,806 | -3% | -$19,455 | |||||
| D | 2020-02-03 | TCDA | Otto Dawn Parsell | SVP, Clinical Development | S - Sale+OE | $36.86 | -4,250 | 255 | -94% | -$156,668 | |||||
| D | 2020-02-03 | TCDA | Hejlek Edward J | SVP, GC, Secy. | S - Sale+OE | $36.42 | -10,000 | 19,153 | -34% | -$364,169 | |||||
2020-02-03 | TCDA | Klaerner Gerrit | Pres, CEO | S - Sale | $36.33 | -4,000 | 616,644 | -1% | -$145,330 | ||||||
2020-01-15 | TCDA | Klaerner Gerrit | Pres, CEO | S - Sale | $35.26 | -4,000 | 620,644 | -1% | -$141,040 | ||||||
| D | 2020-01-02 | TCDA | Otto Dawn Parsell | SVP, Clinical Development | S - Sale+OE | $37.04 | -4,250 | 255 | -94% | -$157,421 | |||||
| D | 2020-01-02 | TCDA | Hejlek Edward J | SVP, GC, Secy. | S - Sale+OE | $37.02 | -10,000 | 19,153 | -34% | -$370,151 | |||||
2020-01-02 | TCDA | Klaerner Gerrit | Pres, CEO | S - Sale | $37.15 | -4,000 | 624,644 | -1% | -$148,607 | ||||||
| D | 2019-12-23 | TCDA | Stahl Wilhelm | Chief Tech Officer, SVP | S - Sale+OE | $38.91 | -3,000 | 14,806 | -17% | -$116,730 | |||||
| D | 2019-12-20 | TCDA | Hejlek Edward J | SVP, GC, Secy. | S - Sale+OE | $38.17 | -15,000 | 14,882 | -50% | -$572,550 | |||||
2019-12-18 | TCDA | Klaerner Gerrit | Pres, CEO | S - Sale | $38.91 | -31,750 | 628,644 | -5% | -$1,235,457 | ||||||
2019-12-10 | TCDA | Coufal Sandra I | Dir, 10% | S - Sale | $43.20 | -2,333 | 6,645,292 | 0% | -$100,794 | ||||||
2019-12-11 | TCDA | Klaerner Gerrit | Pres, CEO | S - Sale | $43.50 | -7,572 | 660,394 | -1% | -$329,346 | ||||||
2019-12-11 | TCDA | Bonita David P | Dir, 10% | S - Sale | $40.00 | -1,500,000 | 9,619,791 | -13% | -$60,000,000 | ||||||
2019-12-11 | TCDA | Orbimed Advisors LLC | Dir, 10% | S - Sale | $40.00 | -1,500,000 | 9,619,791 | -13% | -$60,000,000 | ||||||
2019-12-10 | TCDA | Klaerner Gerrit | Pres, CEO | S - Sale | $43.28 | -3,948 | 667,966 | -1% | -$170,869 | ||||||
| M | 2019-11-29 | TCDA | Klaerner Gerrit | Pres, CEO | S - Sale | $39.65 | -8,000 | 671,914 | -1% | -$317,160 | |||||
| D | 2019-11-26 | TCDA | Otto Dawn Parsell | SVP, Clinical Development | S - Sale+OE | $39.60 | -5,746 | 0 | -100% | -$227,549 | |||||
2019-11-26 | TCDA | Alpern Robert J | Dir | S - Sale | $39.59 | -1,000 | 137,390 | -1% | -$39,590 | ||||||
2019-11-22 | TCDA | Coufal Sandra I | Dir, 10% | S - Sale | $41.00 | -180,864 | 6,647,625 | -3% | -$7,415,432 | ||||||
2019-11-22 | TCDA | Isern Brian M. | possible member of 10% group, 10% | S - Sale | $41.00 | -180,864 | 6,423,493 | -3% | -$7,415,432 | ||||||
| M | 2019-11-20 | TCDA | Coufal Sandra I | Dir, 10% | S - Sale | $40.62 | -303,500 | 6,828,489 | -4% | -$12,326,893 | |||||
| M | 2019-11-20 | TCDA | Isern Brian M. | possible member of 10% group, 10% | S - Sale | $40.62 | -301,267 | 6,604,357 | -4% | -$12,237,058 | |||||
| D | 2019-11-20 | TCDA | Stahl Wilhelm | Chief Tech Officer, SVP | S - Sale+OE | $40.81 | -814 | 14,806 | -5% | -$33,219 | |||||
2019-11-20 | TCDA | Alpern Robert J | Dir | S - Sale | $40.65 | -2,439 | 138,390 | -2% | -$99,145 | ||||||
| M | 2019-11-18 | TCDA | Parker Geoffrey M. | Chief Fin. Officer, SVP | P - Purchase | $34.30 | +20,000 | 191,122 | +12% | +$686,016 | |||||
2019-11-12 | TCDA | Alpern Robert J | Dir | S - Sale | $39.92 | -1,159 | 140,829 | -1% | -$46,267 | ||||||
| D | 2019-11-12 | TCDA | Stahl Wilhelm | Chief Tech Officer, SVP | S - Sale+OE | $39.97 | -836 | 14,806 | -5% | -$33,415 | |||||
| D | 2019-11-07 | TCDA | Stahl Wilhelm | Chief Tech Officer, SVP | S - Sale+OE | $39.97 | -2,910 | 14,806 | -16% | -$116,313 | |||||
2019-11-07 | TCDA | Alpern Robert J | Dir | S - Sale | $39.93 | -3,953 | 141,988 | -3% | -$157,843 | ||||||
2019-11-07 | TCDA | Coufal Sandra I | Dir, 10% | S - Sale | $40.02 | -100 | 7,131,989 | 0% | -$4,002 | ||||||
| M | 2019-11-05 | TCDA | Alpern Robert J | Dir | S - Sale | $39.87 | -1,832 | 145,941 | -1% | -$73,047 | |||||
| DM | 2019-11-05 | TCDA | Stahl Wilhelm | Chief Tech Officer, SVP | S - Sale+OE | $40.02 | -1,039 | 14,806 | -7% | -$41,578 | |||||
| D | 2019-11-04 | TCDA | Stahl Wilhelm | Chief Tech Officer, SVP | S - Sale+OE | $39.67 | -2,651 | 14,806 | -15% | -$105,160 | |||||
2019-11-04 | TCDA | Alpern Robert J | Dir | S - Sale | $39.84 | -2,617 | 147,773 | -2% | -$104,261 | ||||||
| D | 2019-11-01 | TCDA | Veitinger Klaus R Dr | Dir | S - Sale+OE | $38.88 | -5,250 | 144,203 | -4% | -$204,103 | |||||
2019-11-01 | TCDA | Klaerner Gerrit | Pres, CEO | S - Sale | $38.54 | -49,000 | 679,914 | -7% | -$1,888,556 | ||||||
| D | 2019-11-01 | TCDA | Lockey Claire | Chief Dev. Officer, SVP | S - Sale+OE | $38.32 | -10,548 | 0 | -100% | -$404,188 | |||||
2019-11-01 | TCDA | Coufal Sandra I | Dir, 10% | S - Sale | $38.78 | -2,338 | 7,132,089 | 0% | -$90,676 | ||||||
| D | 2019-10-28 | TCDA | Otto Dawn Parsell | SVP, Clinical Development | S - Sale+OE | $37.25 | -5,300 | 0 | -100% | -$197,438 | |||||
2019-10-28 | TCDA | Klaerner Gerrit | Pres, CEO | S - Sale | $37.26 | -4,000 | 728,914 | -1% | -$149,035 | ||||||
| D | 2019-10-25 | TCDA | Veitinger Klaus R Dr | Dir | S - Sale+OE | $36.30 | -5,250 | 147,703 | -3% | -$190,575 | |||||
2019-10-25 | TCDA | Alpern Robert J | Dir | S - Sale | $36.52 | -11,000 | 150,390 | -7% | -$401,739 | ||||||
| D | 2019-10-25 | TCDA | Stahl Wilhelm | Chief Tech Officer, SVP | S - Sale+OE | $36.37 | -5,000 | 14,806 | -25% | -$181,846 | |||||
| D | 2019-10-03 | TCDA | Stahl Wilhelm | Chief Tech Officer, SVP | S - Sale+OE | $31.16 | -2,000 | 14,806 | -12% | -$62,320 | |||||
| D | 2019-10-01 | TCDA | Lockey Claire | Chief Dev. Officer, SVP | S - Sale+OE | $30.76 | -10,000 | 0 | -100% | -$307,572 | |||||
2019-10-01 | TCDA | Klaerner Gerrit | Pres, CEO | S - Sale | $31.07 | -11,223 | 732,914 | -2% | -$348,663 | ||||||
2019-09-30 | TCDA | Klaerner Gerrit | Pres, CEO | S - Sale | $30.69 | -10,255 | 744,137 | -1% | -$314,734 | ||||||
| D | 2019-09-26 | TCDA | Veitinger Klaus R Dr | Dir | S - Sale+OE | $31.42 | -4,200 | 151,203 | -3% | -$131,948 | |||||
| D | 2019-09-26 | TCDA | Stahl Wilhelm | Chief Tech Officer, SVP | S - Sale+OE | $31.42 | -2,000 | 14,806 | -12% | -$62,847 | |||||
2019-09-26 | TCDA | Alpern Robert J | Dir | S - Sale | $31.44 | -1,000 | 161,390 | -1% | -$31,440 | ||||||
| D | 2019-09-25 | TCDA | Otto Dawn Parsell | SVP, Clinical Development | S - Sale+OE | $32.50 | -5,300 | 0 | -100% | -$172,257 | |||||
| D | 2019-09-04 | TCDA | Stahl Wilhelm | Chief Tech Officer, SVP | S - Sale+OE | $33.26 | -2,000 | 14,806 | -12% | -$66,525 | |||||
| D | 2019-09-03 | TCDA | Lockey Claire | Chief Dev. Officer, SVP | S - Sale+OE | $33.76 | -10,000 | 0 | -100% | -$337,627 | |||||
| D | 2019-08-28 | TCDA | Otto Dawn Parsell | SVP, Clinical Development | S - Sale+OE | $33.69 | -5,000 | 0 | -100% | -$168,455 | |||||
2019-08-28 | TCDA | Klaerner Gerrit | Pres, CEO | S - Sale | $33.71 | -4,000 | 754,392 | -1% | -$134,840 | ||||||
| D | 2019-08-26 | TCDA | Veitinger Klaus R Dr | Dir | S - Sale+OE | $33.16 | -4,200 | 154,003 | -3% | -$139,286 | |||||
2019-08-26 | TCDA | Alpern Robert J | Dir | S - Sale | $33.19 | -1,000 | 162,390 | -1% | -$33,190 | ||||||
| M | 2019-08-12 | TCDA | Parker Geoffrey M. | Chief Fin. Officer, SVP | P - Purchase | $32.33 | +30,000 | 116,775 | +35% | +$969,870 | |||||
| D | 2019-08-02 | TCDA | Stahl Wilhelm | Chief Tech Officer, SVP | S - Sale+OE | $30.92 | -2,000 | 14,806 | -12% | -$61,840 | |||||
| D | 2019-08-01 | TCDA | Lockey Claire | Chief Dev. Officer, SVP | S - Sale+OE | $32.02 | -10,000 | 0 | -100% | -$320,200 | |||||
| D | 2019-07-29 | TCDA | Otto Dawn Parsell | SVP, Clinical Development | S - Sale+OE | $31.19 | -5,000 | 0 | -100% | -$155,950 | |||||
2019-07-29 | TCDA | Klaerner Gerrit | Pres, CEO | S - Sale | $31.17 | -4,000 | 758,392 | -1% | -$124,680 | ||||||
| D | 2019-07-25 | TCDA | Veitinger Klaus R Dr | Dir | S - Sale+OE | $31.62 | -4,200 | 156,803 | -3% | -$132,818 | |||||
2019-07-25 | TCDA | Alpern Robert J | Dir | S - Sale | $31.60 | -1,000 | 163,390 | -1% | -$31,600 | ||||||
| D | 2019-07-05 | TCDA | Veitinger Klaus R Dr | Dir | S - Sale+OE | $36.30 | -3,492 | 159,603 | -2% | -$126,749 | |||||
| DM | 2019-07-05 | TCDA | Stahl Wilhelm | Chief Tech Officer, SVP | S - Sale+OE | $35.22 | -4,700 | 14,806 | -24% | -$165,549 | |||||
| M | 2019-07-05 | TCDA | Klaerner Gerrit | Pres, CEO | S - Sale | $35.55 | -5,826 | 762,392 | -1% | -$207,097 | |||||
| M | 2019-07-05 | TCDA | Coufal Sandra I | Dir, 10% | S - Sale | $35.92 | -2,000 | 7,134,427 | 0% | -$71,836 | |||||
| AD | 2019-07-03 | TCDA | Stahl Wilhelm | Chief Tech Officer, SVP | S - Sale+OE | $36.91 | -3,300 | 14,806 | -18% | -$121,803 | |||||
2019-07-03 | TCDA | Klaerner Gerrit | Pres, CEO | S - Sale | $37.08 | -6,874 | 768,218 | -1% | -$254,854 | ||||||
| D | 2019-07-03 | TCDA | Veitinger Klaus R Dr | Dir | S - Sale+OE | $36.90 | -9,108 | 161,995 | -5% | -$336,116 | |||||
| D | 2019-07-03 | TCDA | Stahl Wilhelm | Chief Tech Officer, SVP | S - Sale+OE | $36.91 | -3,000 | 14,806 | -17% | -$110,730 | |||||
| D | 2019-07-03 | TCDA | Otto Dawn Parsell | SVP, Clinical Development | S - Sale+OE | $37.04 | -15,407 | 0 | -100% | -$570,675 | |||||
| D | 2019-07-03 | TCDA | Lockey Claire | Chief Dev. Officer, SVP | S - Sale+OE | $37.10 | -40,401 | 0 | -100% | -$1,498,877 | |||||
2019-07-03 | TCDA | Coufal Sandra I | Dir, 10% | S - Sale | $37.03 | -4,000 | 7,136,427 | 0% | -$148,120 | ||||||
2019-07-03 | TCDA | Alpern Robert J | Dir | S - Sale | $37.05 | -3,000 | 164,390 | -2% | -$111,150 | ||||||
2019-04-03 | TCDA | Bonita David P | Dir, 10% | P - Purchase | $36.00 | +225,000 | 11,114,280 | +2% | +$8,100,000 | ||||||
2019-04-03 | TCDA | Orbimed Advisors LLC | Dir, 10% | P - Purchase | $36.00 | +225,000 | 11,114,280 | +2% | +$8,100,000 | ||||||
| D | 2019-03-28 | TCDA | Veitinger Klaus R Dr | Dir | S - Sale+OE | $34.19 | -66,300 | 166,124 | -29% | -$2,266,576 | |||||
| D | 2019-03-28 | TCDA | Stahl Wilhelm | Chief Tech Officer, SVP | S - Sale+OE | $29.99 | -6,000 | 13,832 | -30% | -$179,940 | |||||
| D | 2019-03-28 | TCDA | Otto Dawn Parsell | SVP, Clinical Development | S - Sale+OE | $30.74 | -15,500 | 0 | -100% | -$476,470 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |